Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Completed · Phase 2

Conditions studied: Leukemia, Lymphocytic, Acute

In brief

This goal of this clinical research study is to learn if the combination of methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients) can help to control ALL that has not responded to previous treatment or has come back after a response or chronic myeloid leukemia (CML).

Key facts

Study ID

NCT00905034

Run by

M.D. Anderson Cancer Center

People needed

37

Starts

2009-03-01

Expected to finish

2015-02-01

Last updated by the study team

2015-06-29

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously treated ALL (including Burkitt's lymphoma) or lymphoblastic lymphoma in relapse or primary refractory; without viable stem cell transplant option. Patients with previously treated Philadelphia chromosome positive ALL will be also eligible;
• Chronic myeloid leukemia in blast phase
• Zubrod performance status </= 3;
• Adequate liver function (bilirubin </= 3.0mg/dl, unless considered due to tumor),and renal function (creatinine </= 3.0 mg/dl unless considered due to tumor;
• Age >/= to 1 year
• Understand and voluntarily sign an informed consent form.
• For pediatric patients (age >/= 1 year to </= 18 years), Lansky performance status >/=50
• For pediatric patients (age >/= 1 year to </= 18 years), second or greater relapse

You may not qualify if…

• Pregnant patients
• Prior history of allergic reaction, serious pancreatitis, hemorrhagic or thrombotic event with PEG-l-asparaginase or its components.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.